CH 13584

Drug Profile

CH 13584

Alternative Names: KHL 8425

Latest Information Update: 07 Sep 2000

Price : $50

At a glance

  • Originator Chinoin
  • Class Antiallergics; Antiasthmatics; Antitussives; Bronchodilators
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bronchitis

Most Recent Events

  • 07 Sep 2000 Discontinued-Preclinical for Bronchitis in Hungary (Unknown route)
  • 30 Aug 1999 Sanofi and Synthélabo have now merged to form Sanofi-Synthélabo
  • 05 Feb 1997 The new name for KHL 8425 is CH 13584
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top